Monoclonal Antibodies Market Growth Strategy, Industry Size and Forecast to 2030

Share

Monoclonal Antibodies Market Growth Strategy, Industry Size and Forecast to 2030: SPER Market Research


 Category : Biotechnology

 Published: Nov-2022
 Author: SPER Analyst


Global Monoclonal Antibodies Market is projected to be worth USD 604.06 billion by 2030.

The market is primarily driven by a rise in the incidence of cancer, a rise in the demand for less expensive biosimilar monoclonal antibodies, high demand for biologics, a rise in genomics R&D activities, and the introduction of genetic platforms that are at the cutting edge of technology, such as next-generation sequencing. The market is also expected to grow as a result of an increase in research collaborations for the development of a potent drug pipeline, elevated patient and physician understanding of the benefits of monoclonal antibody (mAb) therapy, and an increase in the approval of blockbuster mAbs for a number of applications.

COVID-19, an unprecedented global public health issue, is anticipated to positively impact the market for monoclonal antibodies and the advancement of monoclonal antibody therapy. Realizing the urgent need for medications to be available on a global basis, multiple SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) neutralising monoclonal antibodies were quickly developed (mAbs). As a result, the COVID-19 infection enhanced growth and opportunity for key monoclonal antibody players over the forecast period.


The Global Monoclonal Antibodies Market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as;  Abbott Laboratories, AbbVie, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Amgen, Astellas Pharma, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Celgene, Celldex Therapeutics, Daiichi Sankyo Company ltd., Eli Lilly, GenScript, GlaxoSmithKline Plc, Hoffman Roche Ltd, Johnson & Johnson, Merck & Co. Inc., Mylan N.V, Norvatis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi, Seattle genetics, Shanghi Junsi bioscience ltd, Sigma-Aldrich Co. LLC, Teva pharmaceutical industries, Thermofischer Scientific.

SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2030. This report provides data for growth estimates and forecasts for product type segment – By Source (Murine, Chimeric, Humanized and Human), By Indication {Cancer (Breast cancer, Colorectal cancer, Lung cancer, Ovarian cancer, Others), Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Others}, By End User (Hospitals, Research Institutes, Others), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies, Neuropharmacological, Cardiovascular and Cerebrovascular, Others), By Production Type (In Vivo and In Vitro).


This report also provides the data for key regional segments of North America, Europe, Asia-Pacific and Rest of the World. 

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.

Join SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us